# Candel Therapeutics, Inc. (CADL) Stock Analysis: Immense Growth Potential with 274.50% Upside

- Link: https://www.directorstalkinterviews.com/candel-therapeutics-inc-cadl-stock-analysis-immense-growth-potential-with-274-50-upside/4121245310
- Published: 2026-03-19T11:34:42+00:00
- Author: Madison Wilson

Candel Therapeutics, Inc. (NASDAQ: CADL) is capturing investor attention with its
promising pipeline in the biotechnology sector, particularly in the realm of cancer
immunotherapies. Headquartered in Needham, Massachusetts, this clinical-stage biopharmaceutical
company is at the forefront of developing innovative treatments for cancer patients,
with a focus on leveraging viral immunotherapy candidates for solid tumors.

Currently trading at $5.04, Candel Therapeutics sits near the lower end of its 52-
week range of $4.39 to $8.90, presenting a potential entry point for investors. 
The stock has seen a slight decrease of 0.03%, but the real story lies in the analyst
projections: an average target price of $18.88, suggesting a colossal upside potential
of 274.50%.

Despite its current lack of profitability, as indicated by a negative EPS of -0.72
and a daunting Return on Equity of -64.58%, Candel’s forward-looking prospects are
generating a buzz. The company’s robust buy ratings—seven in total, with only one
hold and zero sell ratings—illustrate a strong vote of confidence from analysts.
This sentiment is bolstered by an impressive target price range, with the upper 
end reaching as high as $26.00.

Candel’s innovative approach is spearheaded by its enLIGHTEN Discovery Platform,
which employs a herpes simplex virus-based methodology combined with advanced analytics
to discover and develop new viral immunotherapy candidates. Their leading candidates
include CAN-2409, currently in Phase 2a trials for both prostate cancer and non-
small cell lung cancer, and CAN-3110, in Phase Ib trials for recurrent high-grade
glioma. These developments highlight the company’s commitment to addressing unmet
medical needs in oncology.

Financially, Candel is in a challenging position with negative free cash flow of-
$46 million, reflecting the typical cash-intensive nature of biotech research and
development. The absence of revenue growth and net income data is a reminder of 
the inherent risks and long-term horizon typical of investments in the biotechnology
sector. However, the company’s focus on cutting-edge therapies offers significant
potential for breakthrough success.

Technical indicators show a divergence between Candel’s current price and its moving
averages, both sitting at $5.54, suggesting potential undervaluation. The Relative
Strength Index (RSI) stands at a notably low 10.79, indicating the stock is potentially
oversold, which could attract contrarian investors.

For those with an appetite for high risk and high reward, Candel Therapeutics offers
a unique opportunity within the biotech space. Its pioneering work in viral-based
cancer immunotherapies and the substantial analyst-rated upside make it a stock 
to watch closely. However, potential investors should carefully weigh the speculative
nature of this investment against their risk tolerance and investment strategy.

Share on: